Connect to other sites within the UBM Medica Network
Management of a 53-Year-Old Anal Cancer Patient
A 53-year-old man treated for squamous cell carcinoma of the anus presents 4 weeks post-treatment with a 2-cm anal mass. What is the most appropriate next step in his management?
Better Fitness Leads to Lower Cancer Risk for Older Men
Men with high midlife cardiorespiratory fitness have a lower incidence of lung and colorectal cancer; however, this association was not seen for prostate cancer.
Biomarker Combo Could Predict Prostate Cancer Survival
A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer.
Stress Management Improved Quality of Life for Breast Cancer Patients
Women who received cognitive behavioral stress management after surgery for early breast cancer reported better quality of life and lower symptoms of depression.
Cardiovascular Disease Risk in Prostate Cancer Patients on ADT
The FDA requires a risk label on GnRH agonists that indicates the increased risk of cardiovascular disease and diabetes in prostate cancer patients.
Lymph Node Staging in Localized Breast Cancer
In this interview we discuss the current guidelines for lymph node staging in breast cancer and dive into the debate surrounding sentinel node biopsies.
Bone Metastases in Gastrointestinal Stromal Tumors
The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.
Intraperitoneal Chemotherapy Improves Ovarian Cancer Survival
The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.
Crizotinib Yields High Response Rates in ROS1-Rearranged Lung Cancer
A retrospective analysis showed that crizotinib is highly active in lung cancer with ROS1 rearrangements, which are present in about 1% of lung adenocarcinomas.
Later-Line PD-1 Inhibitor Improves Melanoma Outcomes
Advanced melanoma patients who progressed on ipilimumab were more likely to achieve an objective response when treated with nivolumab than with chemotherapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.